Digital Therapeutics Complex Regional Pain Syndrome Market Report 2026

The digital therapeutics complex regional pain syndrome market size has grown rapidly in recent years. It will grow from $1.05 billion in 2025 to $1.24 billion in 2026 at a compound annual growth rate (CAGR) of 17.8%. The growth in the historic period can be attributed to growing awareness of CRPS treatment gaps, rising use of digital health solutions in pain management, increased acceptance of telehealth platforms, early clinical validation of digital therapeutics, growing focus on non-pharmacological therapies.

The digital therapeutics complex regional pain syndrome market size is expected to see rapid growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing adoption of prescription digital therapeutics, rising demand for home-based pain management solutions, expansion of clinician-supported digital care models, growing integration with wearable monitoring devices, increasing reimbursement support for digital therapeutics. Major trends in the forecast period include increasing adoption of software-based pain management programs, growing integration of remote patient monitoring tools, expansion of personalized therapy algorithms, rising use of data-driven symptom tracking platforms, enhanced focus on patient engagement and adherence.

The increasing availability of smartphones and internet connectivity is expected to drive the growth of the digital therapeutics complex regional pain syndrome market going forward. Smartphones and internet connectivity refer to mobile devices that provide access to the internet, allowing users to communicate, browse information, and utilize online services anytime and anywhere. The rising access to smartphones and internet connectivity is fueled by rapid urbanization, as densely populated urban areas create infrastructure needs and economic conditions that accelerate the rollout of mobile networks and broadband services. Greater smartphone and internet penetration supports the growth of digital therapeutics for complex regional pain syndrome by enabling continuous patient engagement, remote monitoring, and personalized therapy delivery through accessible mobile platforms, thereby enhancing treatment adherence, real-time data collection, and overall pain management outcomes. For example, in May 2025, according to the Federal Communications Commission, a US-based government agency, total connections increased by approximately 2.5% between June 2023 and June 2024, reaching 549 million. Mobile connections rose 2.5% year over year to 416 million as of June 2024, while fixed connections grew about 2.3% to 133 million over the same period. Therefore, increasing access to smartphones and internet connectivity is propelling the growth of the digital therapeutics complex regional pain syndrome market.

The increasing healthcare expenditure is expected to drive the growth of the digital therapeutics complex regional pain syndrome market in the coming years. Healthcare expenditure refers to the total financial resources spent by governments, private insurers, businesses, and individuals on medical services, treatments, medications, and related health activities. Healthcare spending is rising due to the growing prevalence of chronic diseases, which require long-term medical management and ongoing therapeutic interventions. Increasing healthcare expenditure supports the demand for cost-effective treatment options such as digital therapeutics, which provide accessible and scalable pain management solutions without the recurring costs associated with traditional in-person care. For example, in June 2025, according to the Centers for Medicare & Medicaid Services, a US government agency, national health expenditures (NHE) rose by 7.5% in 2023 to reach $4.9 trillion, averaging $14,570 per person and accounting for 17.6% of the Gross Domestic Product (GDP). Medicare spending increased by 8.1% to $1.02 trillion, representing 21% of total NHE. Therefore, rising healthcare expenditure is fueling the growth of the digital therapeutics complex regional pain syndrome market.

In November 2023, BehaVR Inc., a US-based digital therapeutics company, merged with Fern Health to establish RealizedCare, a digital care management platform for chronic pain and mental health. Through this merger, BehaVR and Fern Health aim to develop a comprehensive digital care management platform that combines digital therapeutics with traditional support services to provide personalized, scalable, and value-based care for chronic pain and associated mental health conditions. Fern Health Inc. is a US-based digital health company that focuses on delivering virtual, evidence-based chronic pain management solutions.

Major companies operating in the digital therapeutics complex regional pain syndrome market are Abbott Laboratories, Hinge Health Inc., MedBridge Inc., Luna Innovations Inc., BioWave Inc., Kaia Health Software GmbH, XRHealth Inc., Vori Health Inc., AppliedVR Inc., Theranica Bio-Electronics Ltd., PainDrainer Inc., Physitrack Ltd., WellBrain Inc., Vitrue Health Inc., Upswing Health Inc., Flowly Inc., Plethy Inc., PainChek Ltd., Oska Wellness Inc., DarioHealth Corp.

North America was the largest region in the digital therapeutics complex regional pain syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics complex regional pain syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital therapeutics complex regional pain syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the digital therapeutics complex regional pain syndrome market by increasing costs associated with imported wearable devices, sensors, cloud infrastructure hardware, and specialized electronic components used in monitoring and feedback systems. Healthcare providers and digital health developers in North America and Europe are most affected due to reliance on imported hardware and technology infrastructure, while Asia-Pacific faces cost pressures in device manufacturing. These tariffs are increasing development and deployment costs for hybrid software-device solutions. However, they are also encouraging localized device production, domestic software innovation, and greater reliance on cloud-based platforms with reduced hardware dependency.

The digital therapeutics complex regional pain syndrome market research report is one of a series of new reports that provides digital therapeutics complex regional pain syndrome market statistics, including digital therapeutics complex regional pain syndrome industry global market size, regional shares, competitors with a digital therapeutics complex regional pain syndrome market share, detailed digital therapeutics complex regional pain syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics complex regional pain syndrome industry. This digital therapeutics complex regional pain syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digital therapeutics for complex regional pain syndrome are scientifically validated software interventions provided via apps or online platforms that lead patients through proven therapies while monitoring symptoms and treatment adherence. Their goal is to alleviate pain and hypersensitivity, improve function and daily activities, and assist clinicians with remote monitoring and personalized care, aiming to reduce dependence on medications and frequent clinic appointments.

The main product types of digital therapeutics for complex regional pain syndrome include software, devices, and platforms. Software consists of a collection of programs and data that allow computers or devices to perform tasks, manage information, and interact effectively with users or other systems. These products are distributed through multiple channels, including online platforms, pharmacies, direct sales, and other distribution methods. They are applied in various areas, such as pain management, rehabilitation, patient education, and other purposes, and are utilized by a range of end-users, including hospitals, clinics, homecare settings, research institutes, and others.

The digital therapeutics for complex regional pain syndrome market consists of revenues earned by entities by providing services such as prescription digital therapeutic program delivery, virtual reality pain rehabilitation sessions, remote patient monitoring and analytics, tele coaching and behavioral therapy support, and clinician decision-support and care-plan personalization. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics for complex regional pain syndrome market also includes sales of wearable sensors, monitoring devices, neurostimulation systems, and dorsal root ganglion stimulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.